A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer
Status:
Completed
Trial end date:
2017-11-10
Target enrollment:
Participant gender:
Summary
Cellceutix has developed Kevetrin (thioureidobutyronitrile), belonging to an
anti-proliferative p53 activator pharmacological class, for the treatment of cancer.
Nonclinical studies have demonstrated that Kevetrin induces apoptosis by activation of wild
type p53 and induces apoptosis in mutant p53 cells by degradation of oncogenic mutant p53.
In this Phase 2 study, two different short-term treatment regimens of Kevetrin will be
evaluated for safety, tolerability, changes in biomarkers/objective tumor response, and to
evaluate the pharmacokinetics of Kevetrin when administered to subjects with
platinum-resistant/refractory ovarian cancer.